Skip to content

A little signal. Less noise.

DISCOVER

Catalog Categories

CATEGORIES

Categories will appear when the source is connected.

More possibility. Less searching.

A considered collection of AI tools, trials, and opportunities.

RADAR / PostgreSQLConnection pending

ExploreCatalog

A little signal. Less noise.

Loading the catalog…

RADARGood tools open new possibilities.Explore thoughtfully. Create freely.

Skip to content

A little signal. Less noise.

DISCOVER

Catalog Categories

CATEGORIES

Categories will appear when the source is connected.

More possibility. Less searching.

A considered collection of AI tools, trials, and opportunities.

RADAR / PostgreSQLStorage available

ExploreOffer details

A little signal. Less noise.

Back to catalog

诺

诺华 Rhapsido® 获 FDA 批准成为首款症状性皮肤划痕症治疗药物

Readhub

About this offer

诺华口服高选择性布鲁顿酪氨酸激酶抑制剂 Rhapsido®(remibrutinib)获美国 FDA 批准,用于治疗经 H1 抗组胺药仍无法充分控制症状的成人症状性皮肤划痕症,这是首款针对该病症的治疗药物,也是该药物继慢性自发性荨麻疹之后拓展的全新适应症。

Offer details

Provider: Readhub
Source: readhub-rss
Score: 57.26
Confidence: 54%

Source evidence

What RADAR observed and classified to build this opportunity. It is what the source published, not a verification that the offer is still active.

ReadhubObserved: Oct 7, 2026Source reliability: 60%
诺华 Rhapsido® 获 FDA 批准成为首款症状性皮肤划痕症治疗药物. 诺华口服高选择性布鲁顿酪氨酸激酶抑制剂 Rhapsido®(remibrutinib)获美国 FDA 批准,用于治疗经 H1 抗组胺药仍无法充分控制症状的成人症状性皮肤划痕症,这是首款针对该病症的治疗药物,也是该药物继慢性自发性荨麻疹之后拓展的全新适应症。
Open source

诺华 Rhapsido® 获 FDA 批准成为首款症状性皮肤划痕症治疗药物

Opens an external website. Availability and terms may change.

RADARGood tools open new possibilities.Explore thoughtfully. Create freely.

Real offers. Useful details.

The catalog shows persisted RADAR opportunities. Storage availability does not mean sources are verified or offers are active.